Related Experiment Video
Updated: Sep 4, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi1,2, Guan Wang1, Junping Pei1
1Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, 610041, China.
Abstract:
Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head and neck cancer, breast cancer, glioma, cervical cancer, and bladder cancer. First- to third-generation EGFR inhibitors have shown considerable efficacy and have significantly improved disease prognosis. However, most patients develop drug resistance after treatment. The challenge of overcoming intrinsic and acquired resistance in primary and recurrent cancer mediated by EGFR mutations is thus driving the search for alternative strategies in the design of new therapeutic agents. In view of resistance to third-generation inhibitors, understanding the intricate mechanisms of resistance will offer insight for the development of more advanced targeted therapies. In this review, we discuss the molecular mechanisms of resistance to third-generation EGFR inhibitors and review recent strategies for overcoming resistance, new challenges, and future development directions.
Insights
Resistance to epidermal growth factor receptor (EGFR) inhibitors is a major challenge in cancer therapy. This review explores mechanisms of resistance to third-generation EGFR inhibitors and strategies to overcome them for improved cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) is a key target in cancer therapy, regulating cell proliferation and tumor progression.
- EGFR inhibitors have improved outcomes for various cancers, but drug resistance remains a significant clinical hurdle.
- Understanding resistance mechanisms is crucial for developing next-generation targeted therapies.
Purpose of the Study:
- To review the molecular mechanisms underlying resistance to third-generation EGFR inhibitors.
- To discuss current strategies aimed at overcoming EGFR inhibitor resistance.
- To highlight future directions in the development of novel anti-cancer agents targeting EGFR.
Main Methods:
- Literature review of molecular mechanisms of resistance.
- Analysis of recent strategies to overcome resistance to EGFR inhibitors.
- Discussion of challenges and future prospects in targeted cancer therapy.
Main Results:
- Identified diverse molecular mechanisms driving resistance to third-generation EGFR inhibitors.
- Highlighted emerging strategies, including combination therapies and novel drug designs.
- Emphasized the need for deeper understanding of resistance pathways.
Conclusions:
- Overcoming resistance to EGFR inhibitors requires a comprehensive understanding of molecular mechanisms.
- Advanced targeted therapies are being developed to address intrinsic and acquired resistance.
- Future research should focus on innovative strategies to improve long-term patient outcomes in EGFR-driven cancers.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...